Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CLINICAL MICROBIOLOGY

Treat phage like living antibiotics

Bacteriophage therapeutics has emerged as one of the few potential beacons that represent possible solutions to the growing global crisis of antimicrobial resistance. Bringing science to the bedside (and vice versa) will maximize the potential of this compelling opportunity.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Phage evolution: from sideshow to centre stage.

References

  1. 1.

    Rohwer, F., Maughan, H., Youle, M. & Hisakawa, N. Life in Our Phage World: A Centennial Field Guide to the Earth’s Most Diverse Inhabitants (Wholon, 2014).

  2. 2.

    Summers, W. C. Bacteriophage 2, 130–133 (2012).

    Article  Google Scholar 

  3. 3.

    Wommack, K. E. & Colwell, R. R. Microbiol. Mol. Biol. Rev. 64, 69–71 (2000).

    CAS  Article  Google Scholar 

  4. 4.

    Locey, K. J. & Lennon, J. T. Proc. Natl Acad. Sci. USA 24, 5970–5975 (2016).

    Article  Google Scholar 

  5. 5.

    Twort, F. W. Lancet 186, 1241–1243 (1915).

    Article  Google Scholar 

  6. 6.

    Fabijan, A. P. et al. Nat. Microbiol. https://doi.org/10.1038/s41564-019-0634-z (2020).

  7. 7.

    Doogue, M. P. & Polasek, T. M. Ther. Adv. Drug Saf. 4, 5–7 (2013).

    Article  Google Scholar 

  8. 8.

    Ramratnam, B. et al. Nat. Med. 6, 82–85 (2000).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Robert T. Schooley.

Ethics declarations

Competing interests

R. T. S. serves as a consultant to CytoDyn and has stock options in CytoDyn and Antiva Biosciences. He is a member of the Gilead Sciences Scientific Advisory Board and previously served as an uncompensated member of the AmpliPhi Scientific Advisory Board. S. S. holds stock in Adaptive Phage Therapeutics and is an uncompensated scientific advisor to NextBiotics.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Schooley, R.T., Strathdee, S. Treat phage like living antibiotics. Nat Microbiol 5, 391–392 (2020). https://doi.org/10.1038/s41564-019-0666-4

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing